BACKGROUND/ OBJECTIVE: The objective of this cohort study was to understand the positive and negative effects of glucocorticoids (GCs) in patients with systemic lupus erythematosus and myositis from the patients' perspective with the aim of developing a patient-reported outcome measure. METHODS: Included patients were asked to participate in 1 of 5 nominal groups where demographic information and a quality-of-life questionnaire were collected. Patients were asked 2 open-ended questions on (1) benefits and (2) harms related to GC use. We used the Nominal Group Technique, a highly structured consensus method in which responses are generated, shared, and ranked. Descriptive statistics were used to summarize the results. Nominal group sessions took place from April to May 2019. RESULTS: Of 206 patients who were approached, 21 patients participated, 17 with systemic lupus erythematosus and 4 with myositis, predominantly women with more than 10 years of steroid use. The domains ranked highest for GC benefits were disease control (55 votes), fast onset of action (30 votes), increased energy (10 votes), and pain relief (10 votes). The highest-ranked negative effects were bone loss (38 votes) and weight gain (16 votes); psychological effects and damaged internal organs each received 12 votes. CONCLUSIONS: The top-ranked GC effects-both benefits and harms-among patients with systemic rheumatic disease are consistent with the top domains associated with GC use reported with other inflammatory diseases. This study informs the development of a comprehensive patient-reported outcome measure that can be used across inflammatory diseases.
BACKGROUND/ OBJECTIVE: The objective of this cohort study was to understand the positive and negative effects of glucocorticoids (GCs) in patients with systemic lupus erythematosus and myositis from the patients' perspective with the aim of developing a patient-reported outcome measure. METHODS: Included patients were asked to participate in 1 of 5 nominal groups where demographic information and a quality-of-life questionnaire were collected. Patients were asked 2 open-ended questions on (1) benefits and (2) harms related to GC use. We used the Nominal Group Technique, a highly structured consensus method in which responses are generated, shared, and ranked. Descriptive statistics were used to summarize the results. Nominal group sessions took place from April to May 2019. RESULTS: Of 206 patients who were approached, 21 patients participated, 17 with systemic lupus erythematosus and 4 with myositis, predominantly women with more than 10 years of steroid use. The domains ranked highest for GC benefits were disease control (55 votes), fast onset of action (30 votes), increased energy (10 votes), and pain relief (10 votes). The highest-ranked negative effects were bone loss (38 votes) and weight gain (16 votes); psychological effects and damaged internal organs each received 12 votes. CONCLUSIONS: The top-ranked GC effects-both benefits and harms-among patients with systemic rheumatic disease are consistent with the top domains associated with GC use reported with other inflammatory diseases. This study informs the development of a comprehensive patient-reported outcome measure that can be used across inflammatory diseases.
Authors: Eli M Miloslavsky; Ray P Naden; Johannes W J Bijlsma; Paul A Brogan; E Sherwood Brown; Paul Brunetta; Frank Buttgereit; Hyon K Choi; Jean-Francois DiCaire; Jeffrey M Gelfand; Liam G Heaney; Liz Lightstone; Na Lu; Dedee F Murrell; Michelle Petri; James T Rosenbaum; Kenneth S Saag; Murray B Urowitz; Kevin L Winthrop; John H Stone Journal: Ann Rheum Dis Date: 2016-07-29 Impact factor: 19.103
Authors: David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays Journal: J Clin Epidemiol Date: 2010-08-04 Impact factor: 6.437
Authors: Rachel J Black; Susan M Goodman; Carlee Ruediger; Susan Lester; Sarah L Mackie; Catherine L Hill Journal: J Clin Rheumatol Date: 2017-12 Impact factor: 3.517
Authors: Sadaf Asl Baakhtari; Andrew McCombie; Sebastiaan Ten Bokkel Huinink; Peter Irving; Corey A Siegel; Roger Mulder; Chris J Mulder; Richard Gearry Journal: Dig Dis Date: 2017-09-02 Impact factor: 2.404
Authors: J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma Journal: Ann Rheum Dis Date: 2005-08-17 Impact factor: 19.103
Authors: M C van der Goes; J W G Jacobs; M Boers; T Andrews; M A M Blom-Bakkers; F Buttgereit; N Caeyers; E H Choy; M Cutolo; J A P Da Silva; L Guillevin; M Holland; J R Kirwan; J Rovensky; K G Saag; G Severijns; S Webber; R Westhovens; J W J Bijlsma Journal: Ann Rheum Dis Date: 2009-09-17 Impact factor: 19.103
Authors: Joanna C Robson; Jill Dawson; Peter F Cronholm; Susan Ashdown; Ebony Easley; Katherine S Kellom; Don Gebhart; Georgia Lanier; Nataliya Milman; Jacqueline Peck; Raashid A Luqmani; Judy A Shea; Gunnar Tomasson; Peter A Merkel Journal: Rheumatol Int Date: 2017-11-09 Impact factor: 2.631
Authors: Eve M D Smith; Sarah L Gorst; Eslam Al-Abadi; Daniel P Hawley; Valentina Leone; Clarissa Pilkington; Athimalaipet V Ramanan; Satyapal Rangaraj; Arani Sridhar; Michael W Beresford; Bridget Young Journal: Rheumatology (Oxford) Date: 2021-12-01 Impact factor: 7.580